Full-Time

Sterilization and Monitoring Specialist

Updated on 9/3/2026

Solventum

Solventum

10,001+ employees

Global healthcare company: wound care, dental

Compensation Overview

$126.4k - $173.8k/yr

+ Variable incentive pay

No H1B Sponsorship

Ohio, USA

Remote

Remote within the Ohio sales territory, with up to 50% overnight travel anticipated. Relocation assistance may be authorized.

Bachelor's

Category
Sales & Account Management (1)
Required Skills
Microsoft Office
Sales
CRM
Salesforce
Data Analysis
Excel/Numbers/Sheets
Microsoft Outlook
PowerPoint/Keynote/Slides

Get referred to Solventum

See people who can refer or advise you

Requirements
  • A bachelor's degree or higher and four years of sales, clinical, or related experience, or a high school diploma/GED and six years of sales, clinical, or related experience.
  • A current, valid driver's license.
  • Experience with Microsoft Office applications, including Excel, PowerPoint, and Outlook.
  • Legal authorization to work in the country of employment without employment visa sponsorship.
  • Ability to satisfy licenses, vaccinations, and other credentials or qualifications required for entry into healthcare or third-party facilities.
  • Ability to drive a company vehicle and pass pre-employment and ongoing motor vehicle history reviews.
Responsibilities
  • Manage a sales territory focused on customer support, growth, and customer relationships.
  • Manage accounts and territories to deliver sustainable business growth based on targets and quotas.
  • Use data and analytics to inform business planning.
  • Identify and solve customers' financial and clinical priorities and constraints.
  • Use hospital networks and contacts to identify expansion and conversion opportunities.
  • Persuade account stakeholders to advocate for proposed solutions and products.
  • Manage relationships with key clinical and economic stakeholders.
  • Increase the mix of new product introductions.
  • Collaborate with channel, distribution, and kitting partners to manage relationships and align mutually beneficial tactics and programs.
  • Offer new and ongoing in-service education and technical support, and troubleshoot product-related issues as needed.
  • Use publications and industry guidelines to influence product adoption and standardization.
  • Drive contract compliance and standardization opportunities.
  • Consult with clinicians on the safe and effective use of products.
  • Demonstrate proficiency after successfully completing the sales training program.
  • Complete essential business planning requirements and maintain sales call data using Salesforce.
  • Support conferences, trade shows, and symposiums.
Desired Qualifications
  • A proven track record of quota and target attainment.
  • Prior healthcare sales or clinical experience.
  • Proven experience in territory management and business planning.
  • Demonstrated expertise in establishing strong customer relationships with key influencers.
  • A strong understanding of clinical value drivers across care areas.
  • Understanding of cleaning, disinfection, sterilization, and asepsis.
  • Customer-focused selling and closing experience.
  • Experience navigating complex selling cycles.
  • Completion of a formal sales training program.
  • Experience using a customer relationship management system such as Salesforce.
  • Experience navigating new product introductions and the value analysis process.
  • Experience collaborating with distribution channel partners.
  • Outstanding data and analytical skills.

Solventum provides a wide range of healthcare products across four main areas: wound care and surgical supplies, dental and orthodontic tools, health information software, and purification filters for biopharmaceuticals. These products work by combining material science and data science to help hospitals manage patient records, prevent infections during surgery, and filter fluids for medical treatments like dialysis. Unlike many competitors, the company holds a massive portfolio of over 7,300 patents inherited from its history as a 3M division, allowing it to serve over 75% of U.S. hospitals. Its goal is to use this intellectual property and a disciplined business model to find new solutions for healthcare providers and grow within the global medical technology market.

Company Size

10,001+

Company Stage

IPO

Headquarters

Maplewood, Minnesota

Founded

2023

Get referred to Solventum

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 organic sales rose 9.5%, and management lifted EPS guidance to $7.10-$7.20.
  • Dental grew 15.2% organically in Q2 2026, showing pricing and product momentum.
  • Solventum exited nearly 70% of TSAs and targets 90% by end-2026.

What critics are saying

  • ERP advance orders inflated Q2 by about $125 million, and Q3 reverses.
  • HIS now faces separation, and AI-native competitors threaten revenue-cycle workflows by 2027.
  • Thermo Fisher's $4.1 billion filtration acquisition removes Solventum's fastest-growing cash engine.

What makes Solventum unique

  • Solventum controls 3M-origin IP, with 7,300 patents across MedSurg, dental, and filtration.
  • Its $200 million Eagan Innovation Hub centralizes wound care, sterilization, and digital health R&D.
  • Management expects nearly 20 launches through Q1 2028, anchoring category depth.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

5%

2 year growth

8%
Yahoo Finance
Aug 20th, 2026
BrightSpring Health Services posts 23.9% revenue growth as Solventum and Inspire Medical face headwinds

BrightSpring Health Services stands out as a strong long-term healthcare investment, whilst Solventum and Inspire Medical Systems face headwinds, according to recent analysis. Healthcare stocks have surged 27.5% over the past six months, outperforming the S&P 500 by 16.2 percentage points. However, increased venture capital has intensified competition across the sector. BrightSpring, which provides home health care, hospice, and pharmacy services, has achieved 23.9% annual revenue growth over the past two years. Analysts forecast 14.1% revenue growth for the next 12 months. Conversely, Solventum faces weak demand with flat revenue expected, whilst its free cash flow margin has declined 18.2 percentage points over five years. Inspire Medical Systems confronts a forecasted revenue decline of 3.5% for the upcoming year.

Yahoo Finance
Aug 11th, 2026
Solventum beats Q2 estimates with $2.21B revenue, raises EPS guidance 10% amid HIS separation

Healthcare solutions provider Solventum reported second quarter revenue of $2.21 billion, up 2.2% year on year and ahead of analyst estimates of $2.15 billion. Non-GAAP profit of $2.55 per share beat consensus estimates by 33.8%. The company announced plans to separate its Health Information Systems business to focus on its MedSurg and Dental segments. Management said the move would allow the HIS unit to pursue AI-driven innovation whilst sharpening Solventum's focus as a pure-play MedTech company. Second quarter results were temporarily boosted by approximately $125 million in advanced orders placed ahead of a major ERP system transition, which management expects to reverse next quarter. The company raised its full-year adjusted EPS guidance to $7.15 at the midpoint, a 10% increase. Solventum is nearing completion of its separation from 3M.

Yahoo Finance
Aug 9th, 2026
Solventum raises 2026 outlook with 9.5% Q2 growth boosted by $125M advanced orders and $100M tariff refund

Solventum exceeded expectations in Q2, posting $2.2 billion in sales with 9.5% organic growth. However, this included roughly $125 million in advanced ERP-related orders and a $100 million tariff refund. Excluding these benefits, organic growth was approximately 4% and adjusted EPS was estimated at $1.73. The company raised its 2026 outlook, now expecting 2.5%–3% organic sales growth, a 22.2%–22.7% operating margin, adjusted EPS of $7.10–$7.20, and free cash flow of $200 million–$300 million. Third-quarter growth is expected to decline temporarily as the advanced orders reverse. Solventum also announced plans to separate its Health Information Systems business through a potential spin-off or sale, aiming to focus on its MedSurg and Dental segments.

PR Newswire
Aug 5th, 2026
Solventum Q2 sales up 9.5%, raises 2026 guidance and plans to separate Health Information Systems unit

Solventum reported second quarter 2026 sales of $2.2 billion, up 2.2% on a reported basis and 9.5% organically. The MedTech company posted GAAP diluted earnings per share of $0.53 and adjusted diluted EPS of $2.55, marking a 50.9% increase. Operating cash flow reached $227 million, whilst free cash flow totalled $144 million. The strong performance was driven by volume and product mix across all segments, including advance orders ahead of ERP cutovers. Solventum announced plans to separate its Health Information Systems business segment as part of its transformation strategy. The company raised its full-year 2026 guidance, increasing organic sales growth to 2.5% to 3.0%, adjusted EPS to $7.10 to $7.20, and free cash flow to $200 million to $300 million.

Yahoo Finance
Aug 2nd, 2026
Solventum appoints Neil Zieselman as chief accounting officer

Solventum has appointed Neil Zieselman as Senior Vice President, Controller, and Chief Accounting Officer. He will succeed Mary Wilcox, who is retiring. Zieselman brings experience from Surgery Partners, Stryker Corporation, Covanta Holding Corporation, Cendant Corporation, and Avaya. He is a licensed CPA. The company's stock trades at $85.44. It has delivered a 9.5% return over the past week and 19.1% over the past year. For investors, Zieselman's background in healthcare and corporate finance may influence Solventum's financial controls, reporting quality, and regulatory engagement. His approach could shape disclosure practices and capital allocation commentary in future earnings calls. Interest payments are not well covered by earnings, making any changes under the new Chief Accounting Officer particularly important for risk assessment.